Nonsteroidal anti-inflammatory drugs and cognitive function. Do they have a beneficial or deleterious effect?

Drug Safety

Volumn 19, Issue 6, 1998, Pages 427-433

  Karplus, Theresa M ^a,b   Saag, Kenneth G ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

AGING; ALZHEIMER DISEASE; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; DRUG USE; HEADACHE; HUMAN; INFLAMMATION; PAIN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTE FUNCTION; VERTIGO; VISUAL DISORDER;

AGED; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COGNITION; COGNITION DISORDERS; CONTROLLED CLINICAL TRIALS; HUMANS;

EID: 0032439161     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819060-00001     Document Type: Review

References (32)

1. Baum C, Kennedy DL. Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985; (6): 686-92
2. Chrischilles EA, Lemke JH, Wallace RB, et al. Prevalence and characteristics of multiple analgesic use in an elderly study group. J Am Geriatr Soc 1990; 979-84
3. Cuthbert MF. Adverse reactions to non-steroidal antirheumatic drugs. Curr Med Res Opin 1974 2; 9: 600-10
4. Hoppmann RA, Peden JG, Scott K. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Arch Intern Med 1991; 151: 1309-13
5. Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and ibuprofen in the elderly. Arthritis Rheum 1982; 25 (8): 1013-5
6. Wysenbeek AJ, Klein Z, Nakar S, et al. Assessment of cognitive function in elderly patients treated with naproxen: a prospective study. Clin Exp Rheumatol 1988; 6: 399-400
7. Rozzini R, Ferrucci L, Losonczy K, et al. Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc 1996; 44: 1025-9
8. Sturmer T, Glynn RJ, Field TS, et al. Aspirin use and cognitive function in the elderly. Am J Epidemiol 1996; 143 (7): 683-91
9. Hanlon JT, Schmader KE, Landerman LR, et al. Relation of prescription nonsteroidal antiinflammatory drug use to cognitive function among community-dwelling elderly. AEP 1997; 7 (2): 87-94
10. Saag KG, Rubenstein LM, Chrischilles EA, et al. Nonsteroidal antiinflaminatory drugs and cognitive decline in the elderly. J Rheumatol 1995; 22: 2142-7
11. Jenkinson ML, Bliss MR, Brain AT, et al. Rheumatoid arthritis and senile dementia of the Alzheimer's type. BJR 1989; 28 (1): 86-7
12. The Canadian Study of Health and Aging. The Canadian study of health and aging: risk factors for Alzheimer's disease in Canada. Neurology 1994; 44: 2073-80
13. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990; 40: 1698-707
14. Kukull WA, Larson EB, Stergachis A, et al. Non-steroidal antiinflammalory drug use and risk of Alzheimer's disease [abstract]. Neurology 1994; 44: A237
15. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994; 44: 227-32
16. Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimers disease?: the Rotterdam Study. Neurology 1995; 45: 1441-5
17. Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimers disease and duration of NSAID use. Neurology 1997; 48: 626-32
18. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-7
19. Breteler MMB, Van Duijn CM, Chandra V, et al. Medical history and the risk of Alzheimers disease: a collaborative reanalysis of case-control studies. Int J Epidemiol 1991; 20 (2) Suppl. 2: S36-42
20. Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45: 51-5
21. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11
22. Mortimer JA, Ebbitt B, Jun S-P, et al. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992; 42: 1689-96
23. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151 (8): 1105-13
24. 1-Antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990; 28 (4): 562-7
25. 1-antichymotrypsin in Down's syndrome and Alzheimer's disease. Ann Neurol 1992; 32: 193-7
26. Fillit H, Ding W, Buee L, et al. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neuroscience 1991; 129: 318-20
27. McGeer PL, Akiyama H, Itagaki S, et al. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neuroscience 1989; 107: 341-6
28. Griffin WS, Stanley LC, Ling C, et al. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 7611-5
29. Bauer J, Ganter U, Strauss S, et al. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res Immunol 1992; 143: 650-7
30. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975; 23 (10): 433-41
31. Katzman R, Brown T, Fuld P, et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983; 140 (6): 734-9
32. Perlmutter M. Age differences in adults free recall, cued recall and recognition. J Gerontol 1979; 34: 533-9